Bank of New York Mellon
BCAX

Bank of New York Mellon’s Bicara Therapeutics BCAX Stock Holding History

Bank of New York Mellon’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.58M Buy
120,666
+37,402
+45% +$835K ﹤0.01% 2640
2026
Q1 		$1.66M Sell
83,264
-5,413
-6% -$93.2K ﹤0.01% 2915
2025
Q4 		$1.49M Buy
88,677
+4,143
+5% +$70.8K ﹤0.01% 3012
2025
Q3 		$1.33M Buy
84,534
+4,106
+5% +$46K ﹤0.01% 3042
2025
Q2 		$747K Buy
80,428
+38,236
+91% +$456K ﹤0.01% 3286
2025
Q1 		$550K Buy
42,192
+1,924
+5% +$25.6K ﹤0.01% 3397
2024
Q4 		$701K Buy
+40,268
New +$838K ﹤0.01% 3348

Other funds holding BCAX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Bank of New York Mellon's BCAX Position: Q2 2026 in Review

Bank of New York Mellon increased its Bicara Therapeutics (BCAX) stake by 45% in Q2 2026, buying an estimated $835K and bringing the position to 120,666 shares worth $3.58M. The position accounts for ﹤0.01% of the portfolio, ranked #2640.

Bank of New York Mellon first reported a position in BCAX in Q4 2024 and has held it in 7 quarters since. 55 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Bank of New York Mellon held 120,666 shares of Bicara Therapeutics worth $3.58M as of Q2 2026.
  • Bank of New York Mellon bought 37,402 Bicara Therapeutics shares in Q2 2026, an estimated $835K.
  • Bicara Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2640 holding.
  • Bank of New York Mellon first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 55 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.